Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.

Physiological research·2014
Same author

The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice.

European journal of endocrinology·2014
Same author

Results of retrospective classification of thyroid FNAs according to the Bethesda system: would this have improved accuracy?

Cytopathology : official journal of the British Society for Clinical Cytology·2014
Same author

[Recommendation of the Czech Society of Endocrinology for the treatment of Cushing's syndrome in adults].

Vnitrni lekarstvi·2013
Same author

The effect of immunosuppression on manifestations of sepsis in an animal model of cecal ligation and puncture.

Transplantation proceedings·2013
Same author

[Androgen deficit and diabetes].

Vnitrni lekarstvi·2012

Related Experiment Video

Updated: Jul 13, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

[Thyroid orbitopathy and diabetes].

J Cáp1

  • 1II interní klinika Lékarské fakulty UK a FN, Hradec Králové. capj@lfhk.cuni.cz

Vnitrni Lekarstvi
|July 24, 2007
PubMed
Summary

Thyroid-associated ophthalmopathy (TAO), linked to autoimmune thyroid disease, causes vision loss in some patients. Early treatment with intravenous methylprednisolone is effective, even for those with type 1 diabetes.

Area of Science:

  • Ophthalmology and Endocrinology
  • Autoimmune inflammatory eye disease

Context:

  • Thyroid-associated ophthalmopathy (TAO) is an inflammatory condition frequently associated with autoimmune thyroid diseases (AITD), particularly Graves' disease.
  • TAO affects up to 50% of AITD patients, with 3-5% experiencing severe symptoms like pain, inflammation, double vision, or vision loss.
  • A significant overlap exists between type 1 diabetes mellitus and AITD due to shared pathogenesis and genetics, with up to 30% of type 1 diabetes patients developing AITD.

Purpose:

  • To highlight the importance of assessing TAO activity and severity independently.
  • To emphasize the efficacy of early treatment during the active phase of TAO.
  • To discuss current treatment strategies, including glucocorticoids and surgical interventions.

Summary:

More Related Videos

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

Related Experiment Videos

Last Updated: Jul 13, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

  • Glucocorticoids are a cornerstone treatment for TAO, crucial even in diabetic patients.
  • Intravenous methylprednisolone, administered weekly up to a cumulative dose of 4.5g, is currently the most effective and well-tolerated regimen.
  • Orbital radiotherapy is contraindicated in diabetic patients due to retinopathy risks. Surgical decompression is indicated for severe proptosis and neuropathy, followed by rehabilitative surgery.

    • Impact:

    • Timely and appropriate treatment, particularly with intravenous glucocorticoids, can significantly improve outcomes for TAO patients, including those with type 1 diabetes.
    • Understanding the distinct management needs for TAO activity and severity optimizes patient care.
    • This approach minimizes vision loss and improves quality of life for individuals affected by this autoimmune eye condition.